Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms

NCT04407507 is registered in ClinicalTrials.gov with Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. as lead sponsor.

NCT NCT04407507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04407507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms
Lead sponsor
Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2020
Completion date
January 29, 2021
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19